Targeting the BRAF pathway in haematological diseases
Details
Publication Year 2023-05,Volume 53,Issue #5,Page 845-849
Journal Title
Internal Medicine Journal
Publication Type
Research article
Abstract
Since the recognition of BRAF V600E mutations in the majority of cases of hairy cell leukaemia, Erdheim-Chester disease and Langerhans cell histiocytosis, the targeted oral kinase inhibitors dabrafenib and vemurafenib have been adapted for their treatment. Like other targeted agents, these drugs produce high response rates and predictable but unique side effects. Physician familiarity is essential for the effective use of these agents. We review the Australian experience of BRAF/MEK inhibitor therapy in these rare haematological cancers.
Publisher
Wiley
Keywords
Humans; Australia; Proto-Oncogene Proteins B-raf; *Hematologic Diseases; *Hematologic Neoplasms; *Drug-Related Side Effects and Adverse Reactions
Department(s)
Clinical Haematology; Pathology
PubMed ID
37222093
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-09-05 06:33:26
Last Modified: 2024-07-16 04:21:56

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙